Ignite Creation Date:
2024-05-06 @ 8:08 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06261047
Status:
RECRUITING
Last Update Posted:
2024-02-15
First Post:
2024-02-08
Brief Title:
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
Sponsor:
Shandong Cancer Hospital and Institute
Organization:
Shandong Cancer Hospital and Institute
Study Overview
Official Title:
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer a Multicenter Single-arm Phase II Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma HCC with the emergence of targeted and immunotherapy strategies reshaping first-line therapy Sorafenib a multi-targeted tyrosine kinase inhibitor initially set the standard followed by approvals for lenvatinib regorafenib cabozantinib and ramucirumab Immunotherapy particularly combinations like atezolizumab with bevacizumab has shown superior efficacy over sorafenib Despite these advances second-line therapies offer limited progression-free survival mPFS 2-3 months necessitating new approaches Radiotherapy bolstered by technological advancements has shown promise Techniques like stereotactic body radiotherapy SBRT combined with PD-1 inhibitors achieve significant response rates and survival benefits Combining radiotherapy with targeted immunotherapy has also demonstrated improved outcomes Radiotherapy especially in oligometastatic HCC is increasingly favored due to its ability to enhance local control without increasing toxicity These developments underscore the evolving landscape of HCC treatment towards personalized and multimodal approaches
Detailed Description:
hepatocellular carcinoma stage IIIb oligo progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None